Compound Pharmaceuticals for Dept of Pharmacy, Carl R. Darnall Army Medical Center, Fort Hood, Tx.
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Army, specifically the Carl R. Darnall Army Medical Center at Fort Hood, TX, is soliciting offers for Compound Pharmaceuticals. This is a Firm Fixed-Price contract set aside for Total Small Business. The opportunity aims to procure essential compounded medications for the Department of Pharmacy. Offers are due by February 12, 2026, at 10:00 AM local time.
Scope of Work
This solicitation (W81K0026QA064) requires the provision of specific compound pharmaceuticals, including Succinylcholine Chloride, Oxytocin, L.E.T. (Lidocaine, Epinephrine, Tetracaine), and Phenylephrine HCl. Key requirements include:
- Providing the entirety of the requested compound pharmaceuticals; partial offers are ineligible.
- Products must be compounded using FDA-approved drugs, containers, and diluents.
- Compliance with Trade Agreements Act (TAA) for ingredients.
- Delivery within +/- 10% of USP standards.
- Adherence to the Compounding Quality Act Title I and Current Good Manufacturing Practices (cGMP) (section 503b).
- Labeling according to NPSG.03.04.01 for Joint Commission standards.
- QI/QA certification for every batch and 24/7 customer service.
- Compliance with DEA Licensing for controlled substances.
- Note: Patient-specific prescriptions do not meet bulk compound requirements for CRDAMC.
Contract Details
- Type: Firm Fixed Price
- Period of Performance: Multiple years, generally October 1st to September 30th, from 2026 to 2030.
- Set-Aside: Total Small Business Set-Aside (FAR 19.5)
- NAICS Code: 325412 (Size Standard: 1300 employees)
- Product Service Code: 6505 (Drugs And Biologicals)
Submission & Evaluation
- Offer Due Date: February 12, 2026, at 10:00 AM local time.
- Submission Method: Electronically via email to sheryl.j.egans.civ@health.mil.
- Questions Due: February 3, 2026, 8 AM CST. Responses will be published on SAM.gov by February 5, 2026.
- Evaluation: Award will be made using a Lowest Price Technically Acceptable (LPTA) source selection process.
- Required Documentation: Offerors must provide documented proof of certification/accreditations (FDA or PCAB), USP Chapter compliance, and a Quality Control system. Technical acceptability is mandatory.
- Pricing: Must be submitted for all compound pharmaceuticals, including unit and total extended prices. Prices must be held for ninety (90) days.
Contact Information
Primary Point of Contact: Sheryl Egans (sheryl.j.egans.civ@health.mil, 254-287-8881).